Category Navigation:

Search Site

Handbook of Drug Screening, Second Edition

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Handbook of Drug Screening, Second Edition

By Ramakrishna Seethala, Bristol-Meyers Squibb, Princeton, New Jersey, USA and Litao Zhang, Bristol-Meyers Squibb, Princeton, New Jersey, USA

Email to a Friend
$300.00
Add Items to Cart

This publication is available in both printed and electronic format:

    

Book Specifications

  • Available to Purchase
  • Published: June 2009
  • ISBN: 9781420061680
  • eISBN: 9781420061697
  • Second Edition
  • 504 pages
  • Format: Hardcover
  • Size: 6" x 9"
  • 100 Black and White Illustrations

Quick Overview

Building upon the successes of the first edition, the Second Edition brings you the latest information on how drug screening is done today. With drug screening quickly developing into one of the most essential functions of drug discovery, this is must-read information you cannot afford to be without.

$300.00
Add Items to Cart

Navigation

Building upon the successes of the first edition, the Second Edition brings you the latest information on how drug screening is done today.

With drug screening quickly developing into one of the most essential functions of drug discovery, this is must-read information you cannot afford to be without:

  • BREAKTHROUGH RESEARCH AND DEVELOPMENTS —several new chapters on proteomics, microRNA, high-content screening, lead optimization, compound management, and quantitative high-throughput screening provide the comprehensive updates you need to stay current
  • 46 EXPERT CONTRIBUTORS—with a wealth of experience in drug discovery and development, biotechnology, biochemistry, genomics, proteomics, give you the authoritative guidance you can trust
  • COMPREHENSIVE CONTENT—detailed descriptions and step-by-step analysis on the advances and impacts of target validation, drug screening methods, target family-based screening methods, cell-based assays, and more—help you increase efficiency in the early stages of drug development
  • NEW PLATFORM DEVELOPMENT—for drug screening enables you to reduce assay costs and improve data quality
  • STATE-OF-THE-ART TECHNOLOGIES —used in the academic and industrial drug discovery process help you save time in the preclinical development of drug candidates